Corso online - Numero chiuso

15 and 16 April 2027

6 hours

Online

English

Introduzione

Structured Dialogue with Notified Bodies under the MDR

When should a manufacturer request structured dialogue with a notified body?
Which questions can be discussed, and what information should be prepared beforehand?

This course explores how manufacturers can prepare for and use structured dialogue at different stages of device development and conformity assessment. It considers the framework of MDR Annex VII and Regulation (EU) 2026/977, with particular attention to the scope of these exchanges and the distinction between structured dialogue, consultancy and scientific advice.

Participants will examine how to define meeting objectives, organise supporting information in a Briefing Book and formulate questions supported by a clear rationale. Examples will address pre-clinical, clinical and PMCF topics, as well as common issues arising during documentation reviews.

The course includes a group exercise in which participants prepare a structured dialogue proposal for a device approaching a pivotal clinical investigation. The discussion will explore which questions to raise, how to present the manufacturer’s position and which issues remain the manufacturer’s responsibility.

The aim is to support better preparation and clearer exchanges with notified bodies. Structured dialogue does not replace the manufacturer’s regulatory responsibilities or guarantee a particular assessment outcome or certification timeline.

Programme

Module 1 – The framework for interaction with notified bodies

  • MDR Annex VII and Regulation (EU) 2026/977: requirements relevant to manufacturer–notified body interactions.
  • Review timelines, clock stops and expectations for submissions.
  • The role of structured dialogue within regulatory planning.
  • When to request dialogue and which topics to raise.
  • Common deficiencies and causes of review delays, with examples.
  • Questions and discussion.

Module 2 – Preparing and conducting structured dialogue

  • Structured dialogue, consultancy and scientific advice: differences and boundaries.
  • A comparison with the FDA Pre-Submission and Q-Submission processes.
  • Preparing a meeting request and defining its objectives.
  • Organising a Briefing Book and selecting discussion topics.
  • Conducting the meeting, documenting outcomes and planning follow-up.
  • Considerations for drug-device combination products.
  • Questions and discussion.

Module 3 – Pre-clinical, clinical and PMCF discussion topics

  • Opportunities for dialogue during device development.
  • Pre-clinical development programmes.
  • Clinical development strategies for new and legacy devices, including Article 61(10) MDR.
  • PMCF planning and evidence generation.
  • Potential uses of real-world evidence.
  • Proportionate approaches to clinical evidence requirements.
  • Evidence gaps and the rationale supporting PMS and PMCF plans.
  • Preparing questions on clinical evidence expectations.
  • Questions and discussion.

Module 4 – Group workshop: Developing a structured dialogue case

Participants will work on a case involving a novel medical device that has completed pre-clinical testing and an early clinical study. The manufacturer is preparing for a pivotal clinical investigation and subsequent conformity assessment.

Working in groups, participants will:

  • Identify the main regulatory and clinical milestones.
  • Define the objectives of a proposed structured dialogue.
  • Select topics to discuss with the notified body.
  • Formulate questions and explain the manufacturer’s rationale.
  • Prepare a Briefing Book outline.

Groups will present their proposals and discuss the different approaches with the facilitator, including their limitations and potential pitfalls.

The course is intended for Regulatory Affairs, Clinical Affairs and Quality Assurance professionals involved in preparing submissions or coordinating interactions with notified bodies.
It is also relevant to R&D, Medical Affairs and product development professionals who contribute to regulatory and clinical planning, including those working with combination products or novel devices.

Participant experience
Participants should have a basic understanding of the EU MDR, clinical evaluation, clinical investigations and PMCF. Previous experience of working with a notified body is helpful but not essential.

Presentations and practical examples will be combined with discussion, Q&A and facilitated group exercise. The workshop will focus on preparing a structured dialogue proposal and comparing the reasoning behind different approaches.

Docente/i
Arkan Zwick
Info

Arkan Zwick

Corporate Regulatory Affairs Director

Mr. Arkan Zwick is Corporate Regulatory Affairs Director at a global pharmaceutical and surgical company active in ophthalmology, orthopedics, and aesthetic dermatology. With over 20 years of regulatory experience, he oversees EU compliance with notified bodies and manages global market authorizations across the Americas and Asia-Pacific. His expertise spans regulatory advocacy for drugs, medical devices, combination products, and cosmetics, as well as legal counsel on contracts, mergers & acquisitions, and intellectual property. Arkan holds a master’s degree in law and a PhD in European Law from the University of Vienna. He lectures at University of Applied Sciences (IMC Krems) and speaks regularly at international conferences.


Online Training – 2 modules

MODULE 1 | 15 April 2027 from 9:30 am to 12:30 pm CEST
MODULE 2 | 16 April 2027 from 9:30 am to 12:30 pm CEST

Some days before the online training you will receive all details about the connection.

The course will proceed with a minimum number of participants. Should this number not be reached the registered participants will be notified one week prior to the commencement of the course.

Early Bird: € 690,00* (until 25 March 2027)

Ordinary: € 885,00*

Freelance – Individual – Academy – Public Administration: € 495,00*

* for Italian companies: +22% VAT

The fee includes: tuitions, organizational office assistance, teaching materials and attendance certificate that will be sent after the training via e-mail.

Registrati
Early bird
Acquistabile fino al 25/03/2027
€690,00
Ordinaria
Acquistabile fino al 14/04/2027
€885,00
Freelance - Privato - Accademia - Pubblica Amministrazione
Acquistabile fino al 14/04/2027
€495,00
Svuota

Metodi di pagamento accettati: Bonifico bancario, Carta di credito, PayPal.


Ilaria Butta
Ilaria Butta
Events & Training Manager
Versione Stampabile
Cosa saprai fare dopo il corso
Risultato atteso
Recognise the scope and limitations of structured dialogue with notified bodies.
Risultato atteso
Identify when dialogue may be useful within a device’s regulatory and clinical development pathway.
Risultato atteso
Prepare meeting objectives, questions and supporting information.
Risultato atteso
Develop a Briefing Book outline for a defined case.
Risultato atteso
Distinguish points that require clarification from decisions that remain the manufacturer’s responsibility.
Risultato atteso
Document meeting outcomes and identify appropriate follow-up actions.

<p><span>Online interactive training on Zoom platform. </span></p>
<p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>

Online interactive training on Zoom platform. 

LS Academy will provide the access link to the virtual platform a few days before the training.

<p><span>Online interactive training on Zoom platform. </span></p>
<p><em>LS Academy will provide the access link to the virtual platform a few days before the training.</em></p>